Last edition
News about "COPD therapy"
Transpire Bio Secures FDA Filing Acceptance for Generic High-Strength Trelegy Ellipta ANDA
Transpire Bio receives US Food and Drug Administration (FDA) filing acceptance for its generic high-strength Trelegy Ellipta ANDA with Paragraph IV certification under the Hatch-Waxman Act.
COPD Therapy | 12/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members